NHS Cheshire and Merseyside ICB is preparing to launch a new community-based weight management services this summer, which will include access to the weight loss medication Tirzepatide (also called Mounjaro®). Access to the medication is being rolled out and prioritised to ensure patients with the greatest clinical need can receive it.
Who is it for?
In the first phase, it’s aimed at people with a BMI of 40 or more (or 37.5 for some ethnic groups), plus at least four of the following health conditions:
- Type 2 diabetes
- High blood pressure
- Heart disease
- Abnormal blood fats (dyslipidaemia)
- Obstructive sleep apnoea
Important: Please do not contact your GP yet for a referral. This service is not currently open.
Please read the FAQ section that explains how the medication works, who can prescribe it, alternative services available for weight loss, and considerations such as side effects, ongoing support, and costs.
The rollout is being coordinated carefully, so patients are encouraged to stay updated via NHS Cheshire and Merseyside ICB page: Mounjaro (Tirzepatide) – NHS Cheshire and Merseyside.